Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.39 |
| ▸ | NPY1R | P25929 | 9/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402566 | 0.92 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL14599990 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL7602596 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL14199839 | 0.87 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL9298017 | 0.87 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL24420994 | 0.87 | C3AR1 (0.36) | MEN1KMT2AKISS1RSIRT5 | |
| SCHEMBL21152967 | 0.87 | C3AR1 (0.36) | MEN1KMT2AKISS1RSIRT5 | |
| SCHEMBL20104594 | 0.86 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL19227057 | 0.86 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RALOX15 | |
| SCHEMBL26757511 | 0.86 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312653-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | ENTRADA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
| US-20110052519-A1 | PEPTIDE DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANSING OF THE SKIN, MUCOSAE, SCALP OR NAILS | PUIG, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312653-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | NPY4R 2162/4885NPY1R 1441/4885NPY5R 2593/4885 |
| US-20110052519-A1 | PEPTIDE DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANSING OF THE SKIN, MUCOSAE, SCALP OR NAILS | POLR1C, NGLY1, SSTR4 | NPY4R 222/4885NPY1R 180/4885NPY5R 495/4885 |
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | PRCP, TAP1, DNPEP | NPY4R 3415/4885NPY1R 3263/4885NPY5R 3474/4885 |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | NPY4R 4146/4885NPY1R 4384/4885NPY5R 4236/4885 |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | NPY4R 4146/4885NPY1R 4384/4885NPY5R 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.